The effect that pretransplantation heart failure cause has on pulmonary oxygen uptake (VO2p) kinetics and peak aerobic power (VO2peak) in heart transplant recipients (HTRs) has not been studied. We examined VO2p kinetics and VO2peak in HTRs with previous ischemic heart failure (I-HTRs; n=16, mean age 64+/-6 years) or nonischemic heart failure (NI-HTRs; n=13, mean age 50+/-12 years). HTRs performed an incremental exercise (VO2peak) test and a constant work rate submaximal exercise (VO2p kinetics) test. A monoexponential model was used to determine the phase II VO2p time constant (tau). Phase II VO2p tau was slower in I-HTRs (49+/-10 seconds) than in NI-HTRs (34+/-10 seconds) (p<0.001). No significant difference was found between I-HTRs and NI-HTRs for VO2peak (19.0+/-6.4 vs 23.0+/-8.2 ml.kg-1.min-1, respectively), change in heart rate from rest to steady-state exercise (11+/-8 vs 9+/-9 beats.min-1, respectively), or peak exercise heart rate (140+/-22 vs 144+/-22 beats.min-1, respectively). In conclusion, the prolonged phase II VO2p tau in I-HTRs compared with NI-HTRs suggests that the magnitude of alteration in VO2p kinetics after heart transplantation may be dependent on previous heart failure cause.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.amjcard.2007.01.058 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Assessing platelet-derived extracellular vesicles for potential as therapeutic targets in cardiovascular diseases.
Expert Opin Ther Targets
January 2025
Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, the Netherlands.
Introduction: Cardiovascular disease (CVD) is the leading cause of death worldwide. Platelet-derived extracellular vesicles (PEV) have attracted extensive attention in cardiovascular disease research in recent years because their cargo is involved in a variety of pathophysiological processes, such as thrombosis, immune response, promotion or inhibition of inflammatory response, promotion of angiogenesis as well as cell proliferation and migration.
Areas Covered: This review explores the role of PEV in various cardiovascular diseases (such as atherosclerosis, myocardial infarction, ischemia-reperfusion injury, and heart failure), with relation to its molecular cargo (nucleic acids, bioactive lipids, proteins) and aims to provide new insights in the pathophysiologic role of PEV, and methods for preventing and treating cardiovascular diseases based on PEV.
Medical Problems of Chronic Hypoxia in Highlanders Living on the Tibetan Plateau.
High Alt Med Biol
January 2025
The Research Center for High Altitude Medicine, Qinghai University, Xining, China.
Ri-Li Ge. Medical problems of chronic hypoxia in highlanders living on the tibetan plateau. 00:00-00, 2024.
View Article and Find Full Text PDFA Meta-Analysis on the Efficacy of Noninvasive Positive Pressure Ventilation Combined With Pressure Support Ventilation in Treating Chronic Heart Failure.
Clin Cardiol
January 2025
General Practice, Chengde Central Hospital, Chengde, China.
Objective: To evaluate the clinical efficacy and safety of noninvasive positive pressure ventilation combined with pressure support ventilation (NPPV-PSV) in the treatment of chronic heart failure (CHF) through a meta-analysis.
Methods: A systematic search was conducted using PubMed, Embase, Web of Science, Cochrane Library, CNKI and Wanfang databases to find randomized controlled trials and cohort studies on NPPV-PSV treatment for CHF. The period of search was set from inception until 2024.
Background: The purpose of this study was to investigate whether circulating pyruvate kinase M2 (PK-M2) levels are elevated in the peripheral blood and to assess their association with diagnosis and prognosis in patients with heart failure (HF).
Methods And Results: We conducted a prospective investigation involving 222 patients with HF and 103 control subjects, measuring PK-M2 concentrations using ELISA. The primary outcome, assessed over a median follow-up of 2 years (interquartile range: 776 to 926 days), was the time to the first occurrence of either rehospitalization for worsening HF or cardiovascular death.
Prognostic Implications of Sex in Patients With Heart Failure With Mildly Reduced Ejection Fraction: Results From a Large-Scaled Registry.
J Am Heart Assoc
January 2025
Department of Cardiology, Angiology Haemostaseology and Medical Intensive Care University Medical Centre Mannheim Medical Faculty Mannheim at the University of Heidelberg Mannheim Germany.
Background: The study investigates the prognostic impact of sex and sex-related differences in patients hospitalized with heart failure with mildly reduced ejection fraction (HFmrEF). More data regarding the characterization of patients and their outcomes in the presence of HFmrEF are needed.
Methods And Results: Consecutive patients hospitalized with HFmrEF (ie, left ventricular ejection fraction 41%-49% and signs or symptoms of HF) were retrospectively included at one institution from 2016 to 2022.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!